ESCAPE: an open-label trial of personalized immunotherapy in critically lll COVID-19 patients

E Karakike, GN Dalekos, I Koutsodimitropoulos… - Journal of innate …, 2022 - karger.com
Background: Macrophage activation-like syndrome (MALS) and complex immune
dysregulation (CID) often underlie acute respiratory distress (ARDS) in COVID-19. We …
被引用次数：28 相关文章
[PDF] scienceopen.com

[PDF][PDF] ESCAPE: An Open-Label Trial of Personalized Immunotherapy in Critically lll COVID-19 Patients

E Karakikea, GN Dalekosb, I Koutsodimitropoulosc… - 2021 - scienceopen.com
Background: Macrophage activation-like syndrome (MALS) and complex immune
dysregulation (CID) often underlie acute respiratory distress (ARDS) in COVID-19. We …
[PDF] ru.nl

[PDF][PDF] ESCAPE: An Open-Label Trial of Personalized Immunotherapy in Critically lll COVID-19 Patients

E Karakike, GN Dalekos, I Koutsodimitropoulos… - 2022 - repository.ubn.ru.nl
Background: Macrophage activation-like syndrome (MALS) and complex immune
dysregulation (CID) often underlie acute respiratory distress (ARDS) in COVID-19. We …
[PDF] sepsis.gr

[PDF][PDF] ESCAPE: An Open-Label Trial of Personalized Immunotherapy in Critically lll COVID-19 Patients

E Karakikea, GN Dalekosb, I Koutsodimitropoulosc… - 2021 - sepsis.gr
Background: Macrophage activation-like syndrome (MALS) and complex immune
dysregulation (CID) often underlie acute respiratory distress (ARDS) in COVID-19. We …
[PDF] archive.org

[PDF][PDF] ESCAPE: An Open-Label Trial of Personalized Immunotherapy in Critically Ill COVID-19 Patients

E Karakike, GN Dalekos, I Koutsodimitropoulos… - scholar.archive.org
Rationale Macrophage activation syndrome (MAS) and complex immune dysregulation
(CID) often underlie acute respiratory distress (ARDS) in COVID-19. Objective To investigate …
[HTML] europepmc.org

[HTML][HTML] ESCAPE: An Open-Label Trial of Personalized Immunotherapy in Critically Ill COVID-19 Patients

E Karakike, GN Dalekos, I Koutsodimitropoulos… - 2021 - europepmc.org
Methods In this open-label prospective trial, 102 patients with SOFA (sequential organ
failure assessment) score≥ 2 or ARDS by SARS-CoV-2 were screened for MAS (ferritin …

ESCAPE: An Open-Label Trial of Personalized Immunotherapy in Critically lll COVID-19 Patients

E Karakike, GN Dalekos… - Journal of innate …, 2022 - pubmed.ncbi.nlm.nih.gov
Background Macrophage activation-like syndrome (MALS) and complex immune
dysregulation (CID) often underlie acute respiratory distress (ARDS) in COVID-19. We …
[PDF] academia.edu

[PDF][PDF] ESCAPE: An Open-Label Trial of Personalized Immunotherapy in Critically lll COVID-19 Patients

E Karakikea, GN Dalekosb, I Koutsodimitropoulosc… - 2021 - academia.edu
Background: Macrophage activation-like syndrome (MALS) and complex immune
dysregulation (CID) often underlie acute respiratory distress (ARDS) in COVID-19. We …

ESCAPE: An Open-Label Trial of Personalized Immunotherapy in Critically lll COVID-19 Patients

E Karakike, GN Dalekos… - Journal of Innate …, 2022 - research.regionh.dk
BACKGROUND: Macrophage activation-like syndrome (MALS) and complex immune
dysregulation (CID) often underlie acute respiratory distress (ARDS) in COVID-19. We …

ESCAPE: An Open-Label Trial of Personalized Immunotherapy in Critically Ill COVID-19 Patients

E Karakike, GN Dalekos, I Koutsodimitropoulos… - medRxiv, 2021 - medrxiv.org
Rationale Macrophage activation syndrome (MAS) and complex immune dysregulation
(CID) often underlie acute respiratory distress (ARDS) in COVID-19. Objective To investigate …